Abstract. Genetic alterations in G protein subunit α q (GNAQ) have been reported in numerous types of human cancer. However, the role of GNAQ in human gastric cancer (GC) has not been explored. In the present study, we found that GNAQ was highly expressed in GC patient samples and GNAQ expression was related to patient age, GC differentiation status and adjuvant therapy, as determined by immunohistochemical assay. Lentivirus delivery of short hairpin RNA (shRNA) targeting GNAQ was used to explore the function of GNAQ in GC cells. Silencing of GNAQ markedly suppressed proliferation and colony formation in GC cells, and arrested the cell cycle at the S phase. Mechanistic analysis revealed that knockdown of GNAQ significantly increased the expression of p53 and p21, and decreased cyclin A and p-CDK2 protein expression. Moreover, the phosphorylation of ERK and MEK was also decreased after knockdown of GNAQ as determined by western blotting assay. Overall, our results suggest that GNAQ plays a critical role in regulating GC cell growth and survival via canonical oncogenic signaling pathways including MAPK and p53, and therefore serves as a promising new therapeutic target in GC.
Introduction
Gastric cancer (GC) is the 4th most common cause of cancer-related deaths worldwide. In 2012, there were almost 1,000,000 new cases and over 720,000 deaths (1) . Currently, the standard care for GC patients includes surgery, chemotherapy, radiotherapy and targeted therapy. However, even after multimodal therapy most patients still suffer a high rate of disease recurrence, metastasis and progression (2) . Insight into the molecular mechanisms of gastric carcinogenesis may offer novel, more effective treatment options. Several studies in GC have investigated inhibition of targets such as HER-2, EGFR, VEGFR, mTOR, C-Met and HGF alone or in combination with chemotherapy (3) (4) (5) (6) (7) . However, to date, only two studies have shown promising clinical results of molecular-target agents in GC. First, the TOGA study established trastuzumab in combination with chemotherapy as a new standard of care for patients with HER2-neu-positive advanced or metastatic GC (5) . Second, the REGARD trial demonstrated a survival benefit for ramucirumab in patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma after progression following first-line chemotherapy (3) . Overall, however, the population of patients who can benefit from available targeted therapies is very limited. Therefore, identification of novel GC therapeutic targets is essential.
Alterations at chromosomal position 9q21 have been detected in numerous types of human cancer, including breast and lung cancer, melanoma and glioblastoma (8) (9) (10) (11) . G protein subunit α q (GNAQ) is a protein coding gene and the oncogenic potential of GNAQ was revealed by a systematic analysis of the transforming potential of G proteins and GPCRs (12) . Additionally gain of function mutations in GNAQ or GNA11 oncogenes, encoding persistently active GNAQ, have been previously demonstrated to drive uveal melanoma growth (13) . However, the precise molecular mechanism of the GNAQ contribution to oncogenesis remains unknown and its potential role in GC has yet to be examined. In the present study, we investigated the relationship between GNAQ overexpression and the clinicopathological features of patients with GC, and also determined the biological functions of GNAQ in GC.
Materials and methods
Patient samples. GC patients treated with curative gastrectomy at the First Hospital of Jilin University (Changchun, China) were enrolled in the present study. Tumor specimens were collected from patients between 2011 and 2013. Western blotting. Cell samples were harvested in protein lysis buffer 2X SDS lysis buffer containing 100 mM Tris-HCl (pH 6.8), 10 mM EDTA, 4% SDS and 10% glycine. Protein supernatants were obtained by centrifugation at 12,000 rpm for 10 min at 4̊C. Protein quantification was carried out using a BCA protein assay kit (PF205629; Thermo Fisher Scientific, Waltham, MA USA). Protein was separated using SDS-PAGE and was blotted onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA, USA). After blocking with 5% skim milk in a Tris-buffered saline (TBS) buffer, the membrane was probed with a primary antibody for GNAQ (#13927-1-AP), p53 (#10442-1-AP; both from Proteintech), p21 (#2947; Cell Signaling Technology, Inc., Danvers, MA, USA), cyclin A (#18202-1-AP; Proteintech), p-CDK2 (#2561), CDK2 (#2546), p-ERK (#4370), ERK (#Sc-154) (all from Cell Signaling Technology, Inc.,), p-MEK (#11205) and MEK (#21428) [both from Signalway Antibody (SAB), College Park, MD, USA] with a dilution of 1:1,000, respectively, and GAPDH (#10494-1-AP; Proteintech) as a control with a dilution of 1:100,000 at 4̊C overnight. After rinsing three times with TBS solution buffer, the membrane was incubated with horseradish peroxidase-conjugated secondary goat anti-rabbit IgG antibody (#Sc-2054; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and then washed, followed by visualization using a chemiluminescence analysis system (Tanon-4200; Tianneng, Shanghai, China).
Cell growth assay. Cellular growth of the MGC80-3 control (Con group), MGC80-3-transfected (shCon and shGNAQ groups), SGC7901 control (Con group) and SGC7901 transfected cells (shCon and shGNAQ groups), were assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. After 72 h of incubation, the cells were trypsinized, resuspended, counted and plated in a 96-well plate at a density of 2x10 3 cells/well for five time-points (day 1, 2, 3, 4 and 5). At each time point, MTT solution was added for 4 h followed by acidic isopropanol overnight. The absorbance at 595 nm was assessed to evaluate cell growth. The experiment was performed in triplicate for each data point.
Cell colony formation assay. A total of 500 cells for each group including the MGC80-3 control cells (Con group), MGC80-3 transfected cells (shCon and shGNAQ groups), SGC7901 control cells (Con group) and SGC7901-transfected cells (shCon and shGNAQ groups), were seeded into each well of a 6-well plate. The culture medium was changed every three days, and cells were cultured for 9 days at 37̊C. Subsequently, the cells were washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde for 30 min, and then stained with 0.1% crystal violet for 20 min. The cell colonies were then counted under a light microscope (CH-2; Olympus) and photographed under a digital camera (Nikon, Tokyo, Japan). The experiments were performed in triplicate.
Cell cycle analysis. The MGC80-3 control cells (Con group), MGC80-3-transfected cells (shCon and shGNAQ groups), SGC7901 control cells (Con group) and SGC7901-transfected cells (shCon and shGNAQ groups) were trypsinized, washed twice in cold PBS with 0.1% bovine serum albumin, and fixed with 75% ethanol overnight. Before being run on the flow cytometer, the cells were washed twice again as aforementioned and incubated with 5 µl RNase (200 U/ml, DNase-free) for 15 min. The cells were then stained with 10 µg/ml propidium iodide for at least 1 h in the dark. The cell cycle distribution was analyzed by a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). Each experiment was performed in triplicate.
Statistical analysis. Results were analyzed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). Data are presented as the mean ± SD. Statistical significance was determined by Student's t-test. The characteristics of two GC patient groups were compared using the χ 2 test. DFS and OS curves were estimated using the Kaplan-Meier method. A p-value <0.05 was considered statistically significant.
Results

GNAQ expression in GC patient samples is significantly higher in the regions with carcinoma vs. normal tissues.
To examine GNAQ expression in the surgical tissue of GC patients, we performed immunohistochemistry (IHC) on surgical specimens from 280 GC patients with a history of gastrectomy. Higher expression of the GNAQ protein was observed in the regions with carcinoma as compared to normal adjacent tissues >5 cm distance from the tumor tissue (76.4 vs. 50.7%, p<0.001; Table I ). GNAQ overexpression was observed in all stages (I-IV) of GC and was not significantly different between the stages (Fig. 1) . These data suggest that GNAQ expression is dysregulated in GC patient samples.
GNAQ overexpression is associated with the age and histological subtype of GC patients. A total of 280 GC patients treated with gastrectomy were enrolled in this retrospective, pilot cohort study. We evaluated the clinicopathological features of GC patients according to the GNAQ expression status in the cancer tissues. No significant difference was found in gender, stage and tumor location between patients according to the GNAQ expression status (p= 0.256, 0.264 Table I . GNAQ expression in surgical specimens of the gastric cancer patients (n=280). Table II . Association between patient characteristics and GNAQ expression in gastric carcinoma tissues (n=280). and 0.106, respectively; Table II), however, the age and histological differentiation were significantly associated with GNAQ expression. Higher expression levels of GNAQ were found in the tumor tissues of older patients (≥60 years) compared with younger patients (<60 years, 88.5 vs. 68.3%, p<0.001; Table II ). Furthermore, GNAQ overexpression was observed in patients with worse histological characteristics (87.5 vs. 69%, p<0.001; Table II) .
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GNAQ expression is not correlated with clinical outcomes.
To estimate the prognostic value of GNAQ overexpression in cancer tissues, we used Kaplan-Meier survival analysis to compare clinical outcomes between GNAQ-positive and -negative patients. All 280 eligible patients were analyzed for DFS and OS. Median follow-up was 40.2 months (from 3.8 to 59.6 months). However, no difference was observed in the DFS and OS of GC patients after gastrectomy between GC patients with GNAQ-positive and -negative tumors (median DFS, 42.288 vs. 40.308 months, p= 0.496, and median OS, 45.675 vs. 44.076 months, p=0.430, respectively) ( Fig. 2A and B) . Subgroup analysis of the survival time according to age, histological differentiation and with the application of adjuvant treatment or without were analyzed in the positive GNAQ expression group and negative GNAQ expression group (Fig. 2C-N) . However, no significant difference was observed in the survival time between GNAQ-positive and negative GC patients.
Expression of GNAQ in GC cells.
To analyze the expression of GNAQ in different GC cells, we performed western blotting assay to estimate the expression in MGC80-3, SGC7901 and AGS cell lines. As shown in Fig. 3A , The GNAQ expression levels ranked as SGC7901 > MGC80-3 > AGS.
GNAQ knockdown inhibits cellular growth and colony formation.
To investigate the function of the GNAQ gene in GC, the lentivirus targeting the GNAQ gene [shGNAQ (S1) group and shGNAQ (S2) group] and negative control (shCon group) was infected into MGC80-3 cells. We performed qRT-PCR and western blotting assay to estimate the GNAQ knockdown efficiency in MGC80-3 cells and found that both the mRNA and protein levels of GNAQ were significantly decreased in the shGNAQ group as compared to the blank control (Con group) and shCon group (p<0.001; Fig. 3A and B) . Moreover, the GNAQ protein levels in the SGC7901 cells were significantly decreased in the shGNAQ group compared to the blank control (Con group) and shCon group (Fig. 4A) . Subsequently, MTT and colony formation assays were further performed to examine the influence of GNAQ on GC cell growth. As shown in Figs. 3C and 4B, the cellular proliferation in the shGNAQ group was markedly lower compared with the control groups (Con and shCon groups) in vitro. Similarly, GNAQ silencing obviously decreased the colony formation ability of the MGC80-3 and SGC7901 cells in size and number when compared with the Con and shCon groups (p<0.001; Figure 1 . GNAQ is overexpressed in GC surgical specimens of different stages. Histology of GC surgical specimens by SP assays. GNAQ staining shows that there is no significant difference in GNAQ expression in samples from patients with earlier stages (I and II) and later stages (III and IV). GNAQ, G protein subunit α q; GC, gastric cancer; SP, streptavidin-peroxidase. Fig. 3D and E) (p<0.001; Fig. 4C and D) . Although, the cellular proliferation as determined by MTT assay in the shGNAQ (S1) group of the SGC7901 cells was lower compared with the control groups (Con and shCon groups) in vitro (p<0.001) it was not as decreased as in the shGNAQ (S1) group of the MGC80-3 cells. The aforementioned findings indicate that the GNAQ gene may be involved in the cellular growth of GC.
GNAQ knockdown induces GC cell cycle arrest and promotes apoptosis.
To examine the role of GNAQ in GC cell cycle kinetics, we performed flow cytometry. We found that a significantly greater percentage of GNAQ-silenced MGC80-3 cells was observed in the S phase, and cells in the G0/G1 phase presented a decreased population compared with the control groups (Con and shCon groups) (p<0.001; Fig. 5A and B) . Moreover, we observed a similar result in the GNAQ-silenced SGC7901 cells. Cells in the S phase were significantly increased whereas cells in the G0/G1 phase presented a decreased population compared with the control groups (Con and shCon groups) (p<0.001; Fig. 4E ). The cell cycle assay analysis also revealed that knockdown of GNAQ increased the percentage of sub-G1 cells, indicative of an increase in apoptosis (Figs. 5C and 4F) . Therefore, GNAQ gene silencing in GC cells led to an S phase arrest and promoted apoptosis.
GNAQ knockdown significantly increases p53 expression and inhibits cell cycle-related proteins. To determine the mechanism by which GNAQ alters the cell cycle and apoptosis, MGC80-3 cell lysates from different groups (Con, shCon or shGNAQ group) were used for the immunoblot analysis of p53, p21, phospho-CDK2 and other cyclin family members. As shown in Fig. 6A , the expression of p53 was significantly increased in the shGNAQ group compared with the Con and shCon groups. Similarly, higher p21 expression was observed in the knockdown GNAQ cells compared with the controls (Con and shCon groups) . Furthermore, cyclin A and phospho-CDK2 were decreased in cells infected with shGNAQ compared to the controls (Fig. 6A) . Collectively, these data suggested that GNAQ directly or indirectly inhibits p53 and several key regulators of cell cycle signaling.
GNAQ knockdown inhibits MAPK pathway activity.
Mitogen-activated protein kinase (MAPK) signaling regulates cell proliferation in numerous tumor and normal cells. We therefore examined the key components of the MAPK pathway by western blotting assay, and found that knockdown of GNAQ decreased the phosphorylation of two key signaling proteins along the MAPK pathway: ERK and MEK (Fig. 6B) . These data indicated that GNAQ expression was required for MEK/ERK phosphorylation in MGC80-3 cells. 
Discussion
G protein-coupled receptor (GPCR) proteins are a large, diverse family of heterotrimeric transmembrane proteins that function as signal transducers from the extracellular environment to the cellular interior. On account of their critical importance and the variety of GPCR signaling to normal homeostatic function, it is perhaps not surprising that alterations in the activity of GPCRs and their downstream effectors are frequently implicated in the pathogenesis of cancer. Nearly 20% of human tumors are associated with GPCR aberrancies (14) . The GNAQ gene encodes a G protein α subunit of GPCR and has been identified within chromosomal band 9q21, a region that has been associated with many types of human cancer. However, its explicit function in human cancer particularly in gastric cancer (GC) remains largely unclear. Our findings revealed that GNAQ was overexpressed in GC patient samples as compared to normal matched tissue. Furthermore, GNAQ expression was found to be associated with poorly differentiated GC, suggesting that GNAQ may be a useful biomarker. We investigated the prognostic value of GNAQ overexpression and determined that it had no predictive value in patient outcome for the population we sampled. To conclusively determine the prognostic value of GNAQ, a larger patient population may be examined and perhaps additional types of cancer may be investigated in future studies.
The GNAQ gene encodes a G protein α subunit that has long been known to activate downstream signaling molecule phospholipase C (PLC), which cleaves phosphotidylinositol diphosphate into inositol triphosphate and diacylglycerol (DAG) (15). Inositol triphosphate and DAG then signal calcium and protein kinase C (PKC) via phosphorylation (16) . Phosphorylation of PKC can turn on the mitogen-activated protein kinase (MAPK) pathway, which consists of a cascade of kinases including the GTPase Ras, followed by BRAF, MEK and ERK, leading to activation of various transcription factors involved in normal cell growth and proliferation (17) (18) (19) (20) . Excessive activation of MAPK signaling is the primary driver of cell cycle dysfunction and unregulated proliferation in most cancer cells (20) (21) (22) (23) . Our data demonstrated that GNAQ regulates GC proliferation, colony formation, the cell cycle, and either directly or indirectly promotes MEK and ERK phosphorylation. Notably, in the Catalogue of Somatic Mutations in Cancer (COSMIC) v69, there is a high prevalence of GNAQ activating mutations in tumor types known to require the MAPK pathway for pathogenesis including uveal melanomas (32%), cutaneous melanomas (1.4%) and colon adenocarcinoma (1.4%). Additionally, a study by Van Raamsdonk et al identified activating mutations in GNAQ that could function as oncogenic drivers in models of human uveal melanoma. Furthermore, knockdown of GNAQ in the melanoma cell lines they used, resulted in decreased growth and increased apoptosis, consistent with our findings in GC (24) . Ultimately, GNAQ may act as an oncogene in a broad range of human types of cancer by driving MAPK signaling.
p53 is the 'guardian of the genome' and the most commonly mutated tumor suppressor in cancer (25) . In normal unstressed cells, p53 is maintained at a low level by its negative regulators, such as MDM2. In response to a wide variety of stress signals, activated p53 transcriptionally regulates the expression of its target genes to modulate various cellular processes, including apoptosis and cell cycle arrest (26) . p53 provides a critical barrier to the development of cancer by blocking proliferation or eliminating cancer cells. Over the last two decades, numerous p53-responsive genes have been identified, including the gene encoding cyclin-dependent kinase inhibitor p21
Waf1 (alternatively p21
Cip1
), which mediates cell cycle arrest at the G1/S and G2/M phase (27, 28) . CDK2 has high activity during the S phase, which may be due to cyclin A driving the transition from the S phase to mitosis. We observed for the first time that GNAQ is involved in the p53 signaling pathway. Suppression of GNAQ expression in GC cells resulted in increased p53 and p21 expression. The increased expression of p21 inhibited the activity of the cyclin A/CDK2 complex, slowed down cell proliferation and therefore arrested the cells at the S phase. These data suggest that GNAQ may mediate its effects on the cell cycle and apoptosis through p21 via p53 signaling.
Overall we determined that GNAQ regulates GC proliferation, the cell cycle and apoptosis through a multifactorial mechanism involving downstream pathways including MAPK, p53 and CDKs. In precision medicine, whole genome sequencing data along with related molecular information and individual clinical data, are often employed for selecting appropriate and optimal therapies and for the development of targeted drugs in order to achieve accurate medical care. At present, next generation sequencing (NGS) technology is being applied in some clinical studies. GNAQ, as a target, is detected in the serum of GC patients. The present study indicates that GNAQ is a potential target for the treatment of GC patients. The GNAQ inhibitor is expected to be a novel drug for GC patients with activated gene mutations. These observations provide important insight into the functional significance of GNAQ overexpression in GC and indicate that GNAQ may be a novel target for GC treatment.
